Assessment of nucleosides as putative tumor biomarkers in prostate cancer screening by CE-UV
Assessment of nucleosides as putative tumor biomarkers in prostate cancer screening by CE-UV
复制标题
DOI：
10.1007/s00216-017-0297-7
复制
发表时间：
2017-05-01
影响因子：
4.3
通讯作者：
Colnaghi Simionato, Ana Valeria
中科院分区：
文献类型：
--
作者：
Buzatto, Adriana Zardini;Silva, Mariana de Oliveira;Colnaghi Simionato, Ana Valeria
癌症是全球数百万人死亡的原因，但如果早期发现，大多数基础疾病都可以治愈。筛查试验可用于识别早期恶性肿瘤。然而，前列腺癌的主要筛查工具，前列腺特异性抗原测试，具有不合适的灵敏度。由于癌细胞可能影响核苷的消耗和排泄模式，因此这些生物分子是可用于诊断和治疗评估的推定生物标志物。使用先前验证的方法，通过毛细管电泳与紫外-可见光谱检测分析血清中的核苷，我们调查了60例健康人和42例前列腺癌患者的样本。比较两组中核苷类药物浓度，并优化多元偏最小二乘判别分析分类模型用于预测前列腺癌。用独立样本集对模型进行验证，结果正确分类率为82.4%，灵敏度为90.5%，特异性为76.7%。观察到5-甲基尿苷和肌苷的显著下调，这可以指示致癌过程。因此，这些分析物是前列腺癌筛查的潜在候选物。
Cancer is responsible for millions of deaths worldwide, but most base diseases may be cured if detected early. Screening tests may be used to identify early-stage malignant neoplasms. However, the major screening tool for prostate cancer, the prostate-specific antigen test, has unsuitable sensitivity. Since cancer cells may affect the pattern of consumption and excretion of nucleosides, such biomolecules are putative biomarkers that can be used for diagnosis and treatment evaluation. Using a previously validated method for the analysis of nucleosides in blood serum by capillary electrophoresis with UV-vis spectroscopy detection, we investigated 60 samples from healthy individuals and 42 samples from prostate cancer patients. The concentrations of nucleosides in both groups were compared and a multivariate partial least squares-discriminant analysis classification model was optimized for prediction of prostate cancer. The validation of the model with an independent sample set resulted in the correct classification of 82.4% of the samples, with sensitivity of 90.5% and specificity of 76.7%. A significant downregulation of 5-methyluridine and inosine was observed, which can be indicative of the carcinogenic process. Therefore, such analytes are potential candidates for prostate cancer screening.